Beeline Medicines announces upsized US$426.3 million Series A financing

On June 30, 2026, Beeline Medicines Corporation (“Beeline Medicines”) announced the closing of a US$126.3 million Series A extension, bringing its total Series A financing round to US$426.3 million.

The funding came from existing shareholders and investors, including Bain Capital, Canada Pension Plan Investment Board (“CPP Investments”), and Bristol Myers Squibb, and included participation from certain members of the company’s management team.

The proceeds from the upsized Series A will support the initiation of several clinical studies across the company’s broad immunology portfolio, including planned pivotal development of its lead program, afimetoran, in lupus.  

Further information can be found on Globe Newswire’s website.

Beeline Medicines is a clinical‑stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the lives of people living with autoimmune and inflammatory diseases. With a portfolio of potential best-in-class and first-in-disease therapeutic candidates that directly target key pathways governing dysregulated immunological and inflammatory responses, it is developing medicines that have the opportunity to provide durable, life-changing impact.

CPP Investments is a professional investment management organization that manages the Fund in the best interest of the more than 22 million contributors and beneficiaries of the Canada Pension Plan. At March 31, 2025, the Fund totaled C$714.4 billion.